Performance of plasma p‐tau217 and NfL in an unselected memory clinic setting

Plasma phosphorylated tau‐217 (p‐tau217) and neurofilament light (NfL) can differentiate between different dementias in selected cohorts. We aim to test the discrimination potential of these markers in a real‐world cohort.

• Publication year

  2024

• Venue

  Alzheimer's & Dementia

• Publication date

  2024-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/dad2.70003PMID 39583647PMCID 11584915
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease

  2024cited by this paper
• Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer’s pathology

  2024cited by this paper
• Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

  2024influential reference
• Diagnostic performance of plasma pTau 217, pTau 181, Aβ 1–42 and Aβ 1–40 in the LUMIPULSE automated platform for the detection of Alzheimer disease

  2023influential reference
• 2023 Alzheimer's disease facts and figures

  2023cited by this paper
• Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease

  2022cited by this paper
• The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review.

  2022cited by this paper
• Performance of plasma phosphorylated tau 181 and 217 in the community

  2022cited by this paper
• Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia

  2022cited by this paper
• Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217

  2022cited by this paper
• Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort

  2022cited by this paper
• Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders

  2022cited by this paper
• Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy

  2022cited by this paper
• Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays

  2022cited by this paper
• Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias

  2022cited by this paper
• Age‐ and disease‐specific reference values for neurofilament light presented in an online interactive support interface

  2022cited by this paper
• Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status

  2021cited by this paper
• Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau

  2021cited by this paper
• Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays

  2021cited by this paper
• Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline

  2021cited by this paper
• Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.

  2021cited by this paper
• Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies.

  2021cited by this paper
• Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group

  2021cited by this paper
• Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.

  2021cited by this paper
• Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist

  2021cited by this paper
• A neurologist’s perspective on serum neurofilament light in the memory clinic: a prospective implementation study

  2021cited by this paper
• Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.

  2020cited by this paper
• Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease

  2020cited by this paper
• Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study

  2020cited by this paper
• Fluid biomarkers in frontotemporal dementia: past, present and future

  2020cited by this paper
• Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease

  2020cited by this paper
• Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease

  2020cited by this paper
• Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

  2019cited by this paper
• Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid.

  2019cited by this paper
• Alzheimer’s Disease – Why We Need Early Diagnosis

  2019cited by this paper
• Dementia

  2019cited by this paper
• Diagnosis and Management of Dementia: Review.

  2019cited by this paper
• Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood.

  2019cited by this paper
• A broader view of dementia: multiple co-pathologies are the norm.

  2018cited by this paper
• NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease

  2018cited by this paper
• Neurofilaments as biomarkers in neurological disorders

  2018cited by this paper
• Amsterdam Dementia Cohort: Performing Research to Optimize Care

  2018cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2017cited by this paper
• Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis

  2017cited by this paper
• Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β‐amyloid (1–42) in human cerebrospinal fluid

  2016cited by this paper
• Clinical Approach to the Differential Diagnosis Between Behavioral Variant Frontotemporal Dementia and Primary Psychiatric Disorders.

  2015cited by this paper
• Frontotemporal dementia: diagnosis, deficits and management.

  2014cited by this paper
• Optimizing Patient Care and Research: The Amsterdam Dementia Cohort

  2014cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.

  2011cited by this paper
• Dementia

  2008cited by this paper

• Clinical performance of scalable automated p‐tau 217 multi‐analyte algorithmic blood test with reduced intermediate zone using multiplexed digital immunoassay

  2025cites this paper
• Clinical Performance of LucentAD Complete: A Multi-Analyte Algorithmic Blood Test for Detecting Brain Amyloid with a Scalable, Multiplexed Digital Immunoassay

  2025cites this paper
• Plasma ptau217, NfL, GFAP diagnostic performance and biomarker profiles in Alzheimer disease, frontotemporal dementia, and psychiatric disorders, in a prospective unselected neuropsychiatry memory clinic

  2025cites this paper
• High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer’s disease phenotypes in a large mixed dementia cohort

  2025cites this paper
• Plasma phosphorylated tau 217 detects amyloid-β in Neuronal Synuclein Disease

  2025cites this paper
• Plasma proteomic associations with Alzheimer’s disease endophenotypes

  2025influential citation
• Real world diagnostic performance of plasma p-tau217 for early-onset Alzheimer's disease in a cognitive disorders tertiary care setting

  2025cites this paper
• Hearing loss, plasma neurodegenerative biomarkers, and cognitive function: Independent and additive effects

  2025cites this paper
• Plasma p‐tau217, NfL, GFAP diagnostic performance and biomarker profiles in Alzheimer's disease, frontotemporal dementia, and psychiatric disorders, in a prospective unselected neuropsychiatry memory clinic

  2025cites this paper
• High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer’s disease phenotypes in a large mixed-dementia cohort

  2025cites this paper
• Novel blood‐based proteomic signatures across multiple neurodegenerative diseases

  2024cites this paper